AI assistant
Sending…
EXACT Therapeutics AS — Director's Dealing 2021
Dec 5, 2021
3600_dirs_2021-12-05_fc49989d-e300-4243-b32f-d9b79b860199.pdf
Director's Dealing
Open in viewerOpens in your device viewer
Notification of transactions by Primary Insiders and Close Associates
| 1 | Details of the Primary Insider/Close Associate | |||
|---|---|---|---|---|
| a) | Name | Kvåle AS | ||
| 2 | Reason for the notification | |||
| a) | Position/status | The notification concerns a close associate of a | ||
| a Primary insider: COO, Svein Kvåle | ||||
| b) | Initial notification/ | Initial notification | ||
| Amendment | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or | |||
| auction monitor | ||||
| a) | Name | EXACT Therapeutics AS | ||
| b) | LEI | 2138006ZE5JAL39AGD55 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each | |||
| type of transaction; (iii) each date; and (iv) each place where transactions have been | ||||
| conducted | ||||
| a) | Description of the | Nature of the instrument: Share | ||
| financial instrument, type | ||||
| of instrument | Instrument of identification code (ISIN): NO 001 0852213 | |||
| Identification code | ||||
| b) | Nature of the transaction | Sale of shares | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| NOK 17.1806 per share | 1 772 | |||
| d) | Aggregated information | Price: NOK 30 444 | ||
| - Aggregated volume | Volume: 1 772 | |||
| - Price | ||||
| e) | Date of the transaction | 2021-12-03 | ||
| f) | Place of the transaction | MERK – Oslo Børs |
More from EXACT Therapeutics AS
Annual Report
2026
Apr 9
Report Publication Announcement
2026
Apr 9
Share Issue/Capital Change
2026
Mar 26
Declaration of Voting Results & Voting Rights Announcements
2026
Mar 13
Declaration of Voting Results & Voting Rights Announcements
2026
Mar 13
Regulatory Filings
2026
Mar 3
Proxy Solicitation & Information Statement
2026
Feb 27
Report Publication Announcement
2026
Feb 27
Share Issue/Capital Change
2026
Feb 27
Call Transcript
2026
Feb 6